drugset / Trial / NCT00417391
Phase II Study of RR110 in Patients With Active Crohn's Disease
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics profile of 1 and 4 mg/kg/day RR110 administrated orally for 8 weeks in patients with active Crohn's disease.
Timeline
- Start
- 2006-12
- Primary completion
- 2008-05
- Completion
- 2008-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tamibarotene | Small molecule | 1 mg/kg | Oral |
| Subject | Tamibarotene | Small molecule | 4 mg/kg | Oral |